Open AccessVaricella zoster virus encephalitis: a potentially serious complication during treatment with vedolizumab
Author(s) -
Miriam Celada-Sendino,
Lorena Carballo-Folgoso,
Ruth de Francisco,
Isabel PérezMartínez,
Andrés Castaño-García,
Sabino Riestra
Publication year - 2022
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2022.9121/2022
Subject(s) - medicine , vedolizumab , complication , varicella zoster virus , encephalitis , vaccination , virus , virology , disease , immunology , inflammatory bowel disease , surgery
Vedolizumab is a monoclonal antibody that has demonstrated efficacy and a good safety profile in patients with inflammatory bowel disease. Varicella zoster virus encephalitis is a potentially serious complication not previously described with its use, highlighting the importance of vaccination, as well as early diagnosis and treatment of infections in this type of patients.